Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (7691)	7/7/1999 12:54:00 PM
From: jeffbas	Respond to of 78981

GZSP: One additional observation. As I posted on its thread I believe that its business is mediocre. I brought it to the attention of this thread because technical circumstances surrounding the institutional ownership of GENZ, and the issues of the disadvantages of a tracking stock versus the parent company help, created an opportunity which fully met, in my opinion, the parameters we try to get in a value investment. However, I would only give it 1 in 3 odds that this frog will turn into a $20 per share Seprafilm or biotherapeutic prince. It most likely will just turn into a higher priced $5-10 frog. GZSP has also been discussed on the Biotech Valuation thread: Subject 26145